RET and thyroid gland carcinoma: Therefore, the molecular epidemiology of RET fusions is difficult to infer but the frequency of those uncommon RET partners with more overlap between the different series is usually around 1%: ERC1, TRIM24, TRIM27, TRIM33, DOCK1, KIF13A, and KIAA1468. 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 The development and approval of selective RET inhibitors in lung cancer, thyroid cancer or even in a tumor-agnostic strategy, with high efficacy, means that the relevance of accurately identifying RET fusions has never been greater.4